


PHARMACEUTICAL 2023

Lipocine Inc. Rank 38 of 446









PHARMACEUTICAL 2023



Lipocine Inc. Rank 38 of 446



The relative strengths and weaknesses of Lipocine Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lipocine Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Lipocine Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 256%, being 213% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	34,135
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,678
Liabilities, Non-Current	0
Other Assets	3,276
Other Compr. Net Income	-2.3
Other Expenses	0.68
Other Liabilities	230
Other Net Income	1,361
Other Revenues	500
Property and Equipment	132
Research and Development	8,557
Selling, General and Administrative Expense	4,062

Output Variable	Value in 1000 USD
Assets	37,543
Liabilities	1,908
Expenses	12,620
Revenues	500
Stockholders Equity	35,635
Net Income	-10,759
Comprehensive Net Income	-10,760
Economic Capital Ratio	256%

